Efficacy of Combination Therapy with Oseltamivir Phosphate and Azithromycin for Influenza: A Multicenter, Open-Label, Randomized Study
Open Access
- 14 March 2014
- journal article
- clinical trial
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (3), e91293
- https://doi.org/10.1371/journal.pone.0091293
Abstract
Macrolides have antibiotic and immunomodulatory activities, which may have a favorable effect on the clinical outcome of patients with infections, including influenza. This study aimed to evaluate the effects of combination therapy with an anti-influenza agent, oseltamivir, and a single-dose formulation of azithromycin (AZM), which has been used for influenza-related secondary pneumonia, on influenza patients. The primary endpoint was a change in the expression levels of inflammatory cytokines. Secondary endpoints were the time required for resolution of influenza-related symptoms, incidence of complications, and adverse reactions. Patients with seasonal influenza were enrolled in this multicenter, open-label, randomized study. Patients were stratified according to the presence of a high risk factor and were randomized to receive combination therapy with oseltamivir plus an extended-release formulation of AZM (combo-group) or oseltamivir monotherapy (mono-group). We enrolled 107 patients and randomized them into the mono-group (56 patients) or the combo-group (51 patients). All patients were diagnosed with influenza A infection, and none of the patients had comorbid pneumonia. Statistically significant differences were not observed in the expression levels of inflammatory cytokines and chemokines between the 2 groups. The maximum temperature in the combo-group was lower than that in the mono-group on day 3 through day 5 (p = 0.048), particularly on day 4 (p = 0.037). To our knowledge, this is the first prospective, randomized, clinical trial of oseltamivir and AZM combination therapy for influenza. Although the difference in inflammatory cytokine expression level was not statistically significant, combination therapy showed an early resolution of some symptoms. University hospital Medical Information Network (UMIN). UMIN000005371Keywords
This publication has 31 references indexed in Scilit:
- Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumoniaIntensive Care Medicine, 2013
- Effect of Clarithromycin in Inflammatory Markers of Patients with Ventilator-Associated Pneumonia and Sepsis Caused by Gram-Negative Bacteria: Results from a Randomized Clinical StudyAntimicrobial Agents and Chemotherapy, 2012
- Macrolide Antibiotics and Survival in Patients With Acute Lung InjuryChest, 2012
- Azithromycin Inhibits Mucus Hypersecretion from Airway Epithelial CellsMediators of Inflammation, 2012
- Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infectionJournal of Infection, 2012
- Phase III Randomized, Double-Blind Study Comparing Single-Dose Intravenous Peramivir with Oral Oseltamivir in Patients with Seasonal Influenza Virus InfectionAntimicrobial Agents and Chemotherapy, 2011
- Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitisRespiratory Research, 2010
- Azithromycin Reduces Exaggerated Cytokine Production by M1 Alveolar Macrophages in Cystic FibrosisAmerican Journal of Respiratory Cell and Molecular Biology, 2009
- Treatment with Protein Synthesis Inhibitors Improves Outcomes of Secondary Bacterial Pneumonia after InfluenzaThe Journal of Infectious Diseases, 2009
- Comparison of β-Lactam and Macrolide Combination Therapy versus Fluoroquinolone Monotherapy in Hospitalized Veterans Affairs Patients with Community-Acquired PneumoniaAntimicrobial Agents and Chemotherapy, 2007